[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336925-105":59,"doc-detail-336925-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","oncolytic-coxsackievirus-b3-strain-pd-h-is-effective-against-a-broad-spectrum-of-pancreatic-cancer-cell-lines-and-induces-a-growth-delay-in-pancreatic-kpc-cell-tumors-in-vivo","Oncolytic Coxsackievirus B3 Strain PD-H Is Effective Against a Broad Spectrum of Pancreatic Cancer Cell Lines and Induces a Growth Delay in Pancreatic KPC Cell Tumors In Vivo","","Pancreatic cancer remains among the deadliest malignancies, and current treatments show limited effectiveness for advanced pancreatic ductal adenocarcinoma. This study evaluates the oncolytic coxsackievirus B3 strain PD-H as a pancreatic cancer therapy. In vitro, PD-H displays robust replication and strong lytic activity across most pancreatic tumor cell lines, with effects linked to viral receptor mRNA levels and induction of apoptosis. In vivo, intratumoral PD-H significantly inhibits growth of syngeneic pancreatic KPC tumors without virus-related side effects, though progression is not fully halted.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/oncolytic-coxsackievirus-b3-strain-pd-h-is-effective-against-a-broad-spectrum-of-pancreatic-cancer-cell-lines-and-induces-a-growth-delay-in-pancreatic-kpc-cell-tumors-in-vivo/336925/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/oncolytic-coxsackievirus-b3-strain-pd-h-is-effective-against-a-broad-spectrum-of-pancreatic-cancer-cell-lines-and-induces-a-growth-delay-in-pancreatic-kpc-cell-tumors-in-vivo/336925.png","ImageObject",300,407,{"name":92,"@type":93},"Sage","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is PD-H in this study and why is it being tested for pancreatic cancer?","Question",{"text":112,"@type":113},"PD-H is an oncolytic coxsackievirus B3 strain evaluated as a new pancreatic cancer treatment because oncolytic viruses can trigger cancer cell killing and stimulate antitumor immune responses.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does PD-H perform in vitro compared with other coxsackievirus strains?",{"text":117,"@type":113},"PD-H shows robust replication and potent lytic activity in most pancreatic tumor cell lines, outperforming other tested strains, while response patterns differ between strains and cell line sensitivities.",{"name":119,"@type":110,"acceptedAnswer":120},"What are the main in vivo findings after intratumoral PD-H treatment?",{"text":121,"@type":113},"In a syngeneic mouse model with subcutaneous pancreatic tumors, intratumoral PD-H significantly inhibits tumor growth, delays progression, and causes no observed virus-related side effects.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336925,1790644871,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Article  \nOncolytic Coxsackievirus B3 Strain PD-H Is Effective Against a Broad Spectrum of Pancreatic Cancer Cell Lines and Induces a Growth Delay in Pancreatic KPC Cell Tumors In Vivo  \nAnja Geisler 1,*, Babette Dieringer 1, Leslie Elsner 1, Robert Klopfleisch 2, Jens Kurreck 1 and Henry Fechner 1  \nCitation: Geisler, A.; Dieringer, B.; Elsner, L.; Klopfleisch, R.; Kurreck, J.; Fechner, H. Oncolytic Coxsackievirus B3 Strain PD-H Is Effective Against a Broad Spectrum of Pancreatic Cancer Cell Lines and Induces a Growth Delay in Pancreatic KPC Cell Tumors In Vivo. Int. J. Mol. Sci. 2024, 25, 11224 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms252011224  \nAcademic Editors: Benjamin Frey, Dorota Lubgan and Nathalie Britzen-Laurent  \nReceived: 11 September 2024  \nRevised: 10 October 2024  \nAccepted: 16 October 2024  \nPublished: 18 October 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin,  \n10623 Berlin, Germany; [henry.fechner@tu-berlin.de](henry.fechner@tu-berlin.de) (H.F.)  \n2 Institute of Veterinary Pathology, Freie Universität Berlin, 14163 Berlin, Germany  \n* Correspondence: [a.geisler@tu-berlin.de](a.geisler@tu-berlin.de); Tel.: +49-3031419007583  \nAbstract: Pancreatic cancer is one of the deadliest cancers globally, with limited success from existing therapies, including chemotherapies and immunotherapies like checkpoint inhibitors for patients with advanced pancreatic ductal adenocarcinoma (PDAC) . A promising new approach is the use of oncolytic viruses (OV), a form of immunotherapy that has been demonstrated clinical effectiveness in various cancers. Here we investigated the potential of the oncolytic coxsackievirus B3 strain (CVB3) PD-H as a new treatment for pancreatic cancer. In vitro, PD-H exhibited robust replication, as measured by plaque assays, and potent lytic activity, as assessed by XTT assays, in most pancreatic tumor cell lines, outperforming two other coxsackievirus strains tested, H3N-375/1TS and CVA21 . Thus, H3N-375/1TS showed efficient replication and lytic efficiency in distinctly fewer tumor cell lines, while most tumor cells were resistant to CVA21 . The oncolytic efficiency of the three OV largely correlated with mRNA expression levels of viral receptors and their ability to induce apoptosis, as measured by cleaved caspase 3/7 activity in the tumor cells. In a syngeneic mouse model with subcutaneous pancreatic tumors, intratumoral administration of PD-H significantly inhibited tumor growth but did not completely stop tumor progression. Importantly, no virus-related side effects were observed. Although pancreatic tumors respond to PD-H treatment, its therapeutic efficacy is limited. Combining PD-H with other treatments, such as those aiming at reducing the desmoplasticstroma which impedes viral infection and spread within the tumor, may enhance its efficacy.  \nKeywords: pancreatic cancer; oncolytic virus; coxsackievirus; KPC cells; PD-H; CVA21  \n1. Introduction  \nPancreatic cancer currently has the lowest survival rate of all cancers [1] . Early-stage pancreatectomy remains the only effective treatment modality for the management of the disease and the only potential cure [2] . However, even with “curative” resection and concomitant chemotherapy, the 5-year survival rate for patients with PDAC is less than 25%[3] . Chemotherapy, primarily gemcitabine, has been used as first-line treatment for metastatic PDAC for nearly 25 years [4] . Various combination therapies, such as FOLFIRINOX (a combination of folic acid, oxaliplatin, fluorouracil and irinotecan) ","cbCaikM8wEV8kxcn","https://ap.wps.com/l/cbCaikM8wEV8kxcn","pdf",9387299,16,"English","# Introduction\n## Background: pancreatic cancer burden and current therapies\n## Immunotherapy limitations and the tumor microenvironment\n## Rationale for oncolytic viruses (OVs)","[{\"question\":\"What is PD-H in this study and why is it being tested for pancreatic cancer?\",\"answer\":\"PD-H is an oncolytic coxsackievirus B3 strain evaluated as a new pancreatic cancer treatment because oncolytic viruses can trigger cancer cell killing and stimulate antitumor immune responses.\"},{\"question\":\"How does PD-H perform in vitro compared with other coxsackievirus strains?\",\"answer\":\"PD-H shows robust replication and potent lytic activity in most pancreatic tumor cell lines, outperforming other tested strains, while response patterns differ between strains and cell line sensitivities.\"},{\"question\":\"What are the main in vivo findings after intratumoral PD-H treatment?\",\"answer\":\"In a syngeneic mouse model with subcutaneous pancreatic tumors, intratumoral PD-H significantly inhibits tumor growth, delays progression, and causes no observed virus-related side effects.\"}]","Oncolytic Coxsackievirus B3 Strain PD-H Is Effective Against a Broad Spectrum of Pancreatic Cancer Cell Lines and Induces a Growth Delay in Pancreatic KPC Cell Tumors In Vivo | PDF",1790017082,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5e0aa45eeec473b61196094a44962273.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8219f2c1ac0353d3fd827cc78c95d4ba.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2d7925663a253a55946e0d0d4b667a68.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/711334c9a9eabddcba4887229d1f63ec.webp",980,1385]